CymaBay Therapeutics
CBAY
$32.48
Share price
0.00%
Change (1 day)
221.27%
Change (1 year)
Categories
CymaBay Therapeutics (CBAY) - P/B ratio
P/B ratio as of May 2024 : 12.8
According to CymaBay Therapeutics
's latest financial reports the company has a price-to-book ratio of 12.8.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
CymaBay Therapeutics - P/B ratio (from 2014 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 9.17 | -37.59% |
| 2022-12-31 | 14.7 | 582.19% |
| 2021-12-31 | 2.15 | -22.31% |
| 2020-12-31 | 2.77 | 282.44% |
| 2019-12-31 | 0.7245 | -73.61% |
| 2018-12-31 | 2.75 | -42.2% |
| 2017-12-31 | 4.75 | -53.89% |
| 2016-12-31 | 10.3 | 631.02% |
| 2015-12-31 | 1.41 | -86.49% |
| 2014-12-31 | 10.4 | |
| 2013-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.76 | -86.23% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 5.35 | -58.04% | 🇺🇸 USA |
 Xencor XNCR | 2.18 | -82.93% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | -3.15 | -124.69% | 🇺🇸 USA |